SteelPeak Wealth LLC Makes New Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

SteelPeak Wealth LLC acquired a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 8,309 shares of the company’s stock, valued at approximately $229,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of NTLA. Blue Trust Inc. bought a new position in shares of Intellia Therapeutics in the 4th quarter worth $26,000. Signaturefd LLC raised its holdings in Intellia Therapeutics by 89.3% during the fourth quarter. Signaturefd LLC now owns 1,592 shares of the company’s stock worth $49,000 after buying an additional 751 shares during the last quarter. Daiwa Securities Group Inc. lifted its stake in shares of Intellia Therapeutics by 35.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 3,056 shares of the company’s stock valued at $93,000 after buying an additional 793 shares in the last quarter. Spire Wealth Management grew its holdings in shares of Intellia Therapeutics by 3,789.0% during the fourth quarter. Spire Wealth Management now owns 3,889 shares of the company’s stock valued at $119,000 after buying an additional 3,789 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in shares of Intellia Therapeutics during the fourth quarter worth about $206,000. Institutional investors own 88.77% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Truist Financial reaffirmed a “buy” rating and issued a $120.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 24th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $73.00 target price on shares of Intellia Therapeutics in a research report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating and set a $65.00 price target on shares of Intellia Therapeutics in a report on Monday, June 24th. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a research note on Thursday. Finally, Wedbush reaffirmed a “neutral” rating and set a $29.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, April 23rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $69.00.

Intellia Therapeutics Stock Performance

NASDAQ NTLA opened at $22.38 on Monday. Intellia Therapeutics, Inc. has a 52-week low of $19.37 and a 52-week high of $46.50. The company has a 50-day simple moving average of $23.76 and a 200 day simple moving average of $26.28.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($1.06) EPS for the quarter, topping analysts’ consensus estimates of ($1.35) by $0.29. The company had revenue of $28.94 million during the quarter, compared to the consensus estimate of $15.60 million. As a group, analysts anticipate that Intellia Therapeutics, Inc. will post -4.98 earnings per share for the current year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.